381 related articles for article (PubMed ID: 31267692)
1. Apelin inhibition prevents resistance and metastasis associated with anti-angiogenic therapy.
Uribesalgo I; Hoffmann D; Zhang Y; Kavirayani A; Lazovic J; Berta J; Novatchkova M; Pai TP; Wimmer RA; László V; Schramek D; Karim R; Tortola L; Deswal S; Haas L; Zuber J; Szűcs M; Kuba K; Dome B; Cao Y; Haubner BJ; Penninger JM
EMBO Mol Med; 2019 Aug; 11(8):e9266. PubMed ID: 31267692
[TBL] [Abstract][Full Text] [Related]
2. Loss of apelin blocks the emergence of sprouting angiogenesis in experimental tumors.
Azad AK; Campbell KR; Zhabyeyev P; Oudit GY; Moore RB; Murray AG
FASEB J; 2022 Oct; 36(10):e22560. PubMed ID: 36165236
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of endothelial cell phosphoinositide 3-kinase β inhibits tumor angiogenesis and tumor growth.
Azad AK; Zhabyeyev P; Vanhaesebroeck B; Eitzen G; Oudit GY; Moore RB; Murray AG
Oncogene; 2020 Oct; 39(41):6480-6492. PubMed ID: 32879446
[TBL] [Abstract][Full Text] [Related]
4. SU11248, a selective tyrosine kinases inhibitor suppresses breast tumor angiogenesis and growth via targeting both tumor vasculature and breast cancer cells.
Young E; Miele L; Tucker KB; Huang M; Wells J; Gu JW
Cancer Biol Ther; 2010 Oct; 10(7):703-11. PubMed ID: 20686367
[TBL] [Abstract][Full Text] [Related]
5. The anti-angiogenic effect of tryptanthrin is mediated by the inhibition of apelin promoter activity and shortened mRNA half-life in human vascular endothelial cells.
Chang HN; Yeh YC; Chueh HY; Pang JS
Phytomedicine; 2019 May; 58():152879. PubMed ID: 31005035
[TBL] [Abstract][Full Text] [Related]
6. Genetic lineage tracing reveals poor angiogenic potential of cardiac endothelial cells.
Kocijan T; Rehman M; Colliva A; Groppa E; Leban M; Vodret S; Volf N; Zucca G; Cappelletto A; Piperno GM; Zentilin L; Giacca M; Benvenuti F; Zhou B; Adams RH; Zacchigna S
Cardiovasc Res; 2021 Jan; 117(1):256-270. PubMed ID: 31999325
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence.
Wang D; Xiao F; Feng Z; Li M; Kong L; Huang L; Wei Y; Li H; Liu F; Zhang H; Zhang W
Breast Cancer Res; 2020 Sep; 22(1):103. PubMed ID: 32993785
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of the Apelinergic Axis Accelerates Aging, whereas Its Systemic Restoration Improves the Mammalian Healthspan.
Rai R; Ghosh AK; Eren M; Mackie AR; Levine DC; Kim SY; Cedernaes J; Ramirez V; Procissi D; Smith LH; Woodruff TK; Bass J; Vaughan DE
Cell Rep; 2017 Nov; 21(6):1471-1480. PubMed ID: 29117554
[TBL] [Abstract][Full Text] [Related]
9. Endothelial cell-derived Apelin inhibits tumor growth by altering immune cell localization.
Hu L; Hayashi Y; Kidoya H; Takakura N
Sci Rep; 2021 Jul; 11(1):14047. PubMed ID: 34234274
[TBL] [Abstract][Full Text] [Related]
10. Apelin Controls Angiogenesis-Dependent Glioblastoma Growth.
Frisch A; Kälin S; Monk R; Radke J; Heppner FL; Kälin RE
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32545380
[TBL] [Abstract][Full Text] [Related]
11. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
Wu XY; Xu H; Wu ZF; Chen C; Liu JY; Wu GN; Yao XQ; Liu FK; Li G; Shen L
Oncotarget; 2015 Dec; 6(42):44563-78. PubMed ID: 26575424
[TBL] [Abstract][Full Text] [Related]
12. Apelin receptor antagonist boosts dendritic cell vaccine efficacy in controlling angiogenic, metastatic and apoptotic-related factors in 4T1 breast tumor-bearing mice.
Masoumi J; Zainodini N; Basirjafar P; Tavakoli T; Zandvakili R; Nemati M; Ramezani M; Rezayati MT; Ayoobi F; Khademalhosseini M; Khorramdelazad H; Arman R; Jafarzadeh A
Med Oncol; 2023 May; 40(6):179. PubMed ID: 37188900
[TBL] [Abstract][Full Text] [Related]
13. An apelin receptor antagonist prevents pathological retinal angiogenesis with ischemic retinopathy in mice.
Ishimaru Y; Shibagaki F; Yamamuro A; Yoshioka Y; Maeda S
Sci Rep; 2017 Nov; 7(1):15062. PubMed ID: 29118394
[TBL] [Abstract][Full Text] [Related]
14. A novel 2-aminobenzimidazole-based compound Jzu 17 exhibits anti-angiogenesis effects by targeting VEGFR-2 signalling.
Lien JC; Chung CL; Huang TF; Chang TC; Chen KC; Gao GY; Hsu MJ; Huang SW
Br J Pharmacol; 2019 Oct; 176(20):4034-4049. PubMed ID: 31368127
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the Kit ligand/c-Kit axis attenuates metastasis in a mouse model mimicking local breast cancer relapse after radiotherapy.
Kuonen F; Laurent J; Secondini C; Lorusso G; Stehle JC; Rausch T; Faes-Van't Hull E; Bieler G; Alghisi GC; Schwendener R; Andrejevic-Blant S; Mirimanoff RO; Rüegg C
Clin Cancer Res; 2012 Aug; 18(16):4365-74. PubMed ID: 22711708
[TBL] [Abstract][Full Text] [Related]
16. Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects.
Li D; Xie K; Zhang L; Yao X; Li H; Xu Q; Wang X; Jiang J; Fang J
Cancer Lett; 2016 Jul; 377(2):164-73. PubMed ID: 27130666
[TBL] [Abstract][Full Text] [Related]
17. The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer.
Cascone T; Xu L; Lin HY; Liu W; Tran HT; Liu Y; Howells K; Haddad V; Hanrahan E; Nilsson MB; Cortez MA; Giri U; Kadara H; Saigal B; Park YY; Peng W; Lee JS; Ryan AJ; Jüergensmeier JM; Herbst RS; Wang J; Langley RR; Wistuba II; Lee JJ; Heymach JV
Clin Cancer Res; 2017 Sep; 23(18):5489-5501. PubMed ID: 28559461
[No Abstract] [Full Text] [Related]
18. The "inherent vice" in the anti-angiogenic theory may cause the highly metastatic cancer to spread more aggressively.
Wang D; Tan C; Xiao F; Zou L; Wang L; Wei Y; Yang H; Zhang W
Sci Rep; 2017 May; 7(1):2365. PubMed ID: 28539645
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation.
Brossa A; Grange C; Mancuso L; Annaratone L; Satolli MA; Mazzone M; Camussi G; Bussolati B
Oncotarget; 2015 May; 6(13):11295-309. PubMed ID: 25948774
[TBL] [Abstract][Full Text] [Related]
20. Deciphering the anticancer mechanisms of sunitinib.
Pal SK; Figlin RA; Yu H
Cancer Biol Ther; 2010 Oct; 10(7):712-4. PubMed ID: 20716960
[No Abstract] [Full Text] [Related]
[Next] [New Search]
